Claret L - Search Results

1

Simulations to Predict Clinical Trial Outcome of Bevacizumab Plus Chemotherapy vs. Chemotherapy Alone in Patients With First-Line Gastric Cancer and Elevated Plasma VEGF-A.

Han K, Claret L, Piao Y, Hegde P, Joshi A, Powell JR, Jin J, Bruno R. Han K, et al. Among authors: claret l. CPT Pharmacometrics Syst Pharmacol. 2016 Jul;5(7):352-8. doi: 10.1002/psp4.12064. Epub 2016 Jul 12. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27404946 Free PMC article.

2

Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R. Claret L, et al. J Clin Oncol. 2013 Jun 10;31(17):2110-4. doi: 10.1200/JCO.2012.45.0973. Epub 2013 May 6. J Clin Oncol. 2013. PMID: 23650411

3

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.

Claret L, Gupta M, Han K, Joshi A, Sarapa N, He J, Powell B, Bruno R. Claret L, et al. J Clin Pharmacol. 2014 Mar;54(3):253-7. doi: 10.1002/jcph.191. Epub 2013 Oct 22. J Clin Pharmacol. 2014. PMID: 24122760 Clinical Trial.

4

Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation.

Han K, Claret L, Sandler A, Das A, Jin J, Bruno R. Han K, et al. Among authors: claret l. BMC Cancer. 2016 Jul 13;16:473. doi: 10.1186/s12885-016-2455-2. BMC Cancer. 2016. PMID: 27412292 Free PMC article.

5

Simulations using a drug-disease modeling framework and phase II data predict phase III survival outcome in first-line non-small-cell lung cancer.

Claret L, Lu JF, Bruno R, Hsu CP, Hei YJ, Sun YN. Claret L, et al. Clin Pharmacol Ther. 2012 Nov;92(5):631-4. doi: 10.1038/clpt.2012.78. Epub 2012 Aug 22. Clin Pharmacol Ther. 2012. PMID: 22910440 Clinical Trial.

6

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

Bruno R, Mercier F, Claret L. Bruno R, et al. Among authors: claret l. Clin Pharmacol Ther. 2014 Apr;95(4):386-93. doi: 10.1038/clpt.2014.4. Epub 2014 Jan 13. Clin Pharmacol Ther. 2014. PMID: 24419563 Review.

7

Assessment of tumor growth inhibition metrics to predict overall survival.

Claret L, Bruno R. Claret L, et al. Clin Pharmacol Ther. 2014 Aug;96(2):135-7. doi: 10.1038/clpt.2014.112. Clin Pharmacol Ther. 2014. PMID: 25056390 No abstract available.

8

Model-Based Estimates of Tumor Growth Inhibition Metrics Are Time-Independent: A Reply to Mistry.

Claret L, Han K, Bruno R. Claret L, et al. CPT Pharmacometrics Syst Pharmacol. 2017 Apr;6(4):225. doi: 10.1002/psp4.12163. Epub 2017 Apr 11. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 27997740 Free PMC article. No abstract available.

9

On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.

Bruno R, Claret L. Bruno R, et al. Among authors: claret l. Clin Pharmacol Ther. 2009 Aug;86(2):136-8. doi: 10.1038/clpt.2009.97. Clin Pharmacol Ther. 2009. PMID: 19621009

10

A modeling and simulation framework to support early clinical drug development decisions in oncology.

Bruno R, Lu JF, Sun YN, Claret L. Bruno R, et al. Among authors: claret l. J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13. J Clin Pharmacol. 2011. PMID: 20628172 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters